Evogene Ltd. — Regulatory Filings 2022

Jan 11, 2022

Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb�s Anti-PD-1 Opdivo� false

����� ��"�	2 380
EVOGENE LTD
Corporation no: 512838723	10571
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	11/01/2022
	www.isa.gov.il			www.tase.co.il				Reference:	2022-02-005593	Time of broadcast: 13:24 13:24

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onBiomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb�s Anti-PD-1 Opdivo�

6K_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: -1	Date of revision of form structure: 30/12/2021
Address: Gad Feinstein St 13, P.O.B 2100 , Rehovot 76121   , Tel: 08-9311900 , Fax: 08-9466724
E-mail address: ofer.haviv@evogene.com   Company site: www.evogene.com
Previous names of reporting entity:
Name of the Signatory: Masliah Sassi Position of Signatory in the reporting corporation: Director of Legal Affairs & Company Secretary Name of Employer Company:
Address: Gad Feinstein 13 , Rehovot 7612001 Telephone: 08-9311901 Facsimile: 08-9466724 E-mail: sassi.masliah@evogene.com 1